Introduction
============

Acute promyelocytic leukemia (APL) is a relatively rare subtype of acute myelogenous leukemia that occurs in 8--15% of all acute non-lymphoblastic leukemia patients, with a mean incidence of two to three cases per million members of the global population each year ([@b1-ol-07-01-0177]). APL is characterized by pathological coagulation (coagulopathy) involving abnormal accumulation of immature granulocytes, particularly promyelocytes, leading to fibrinolysis and hemostatic failure ([@b1-ol-07-01-0177],[@b2-ol-07-01-0177]). Unlike other leukemia subtypes, optimal treatment of APL requires rapid initiation of all-*trans* retinoic acid (ATRA) therapy and targeted supportive care for APL-specific complications, including bleeding disorders, APL differentiation syndrome, QT prolongation and other ATRA-related toxicities ([@b3-ol-07-01-0177]). The wide-spread clinical employment of combined ATRA regimens, including ATRA and arsenic compounds, has reduced relapse from \~50% to \<10% in adult patients with APL over the past two decades ([@b4-ol-07-01-0177],[@b5-ol-07-01-0177]). However, increased knowledge of the outcomes in this remaining group of treated patients with APL that exhibit relapse is crucial to understanding APL pathophysiology and to improving survival in this patient subpopulation.

APL is caused by the cumulative effects of somatic mutations, ultimately resulting in the development of mutagen-induced carcinogenesis, and often occurs with advanced age ([@b1-ol-07-01-0177]). Cytogenetically, between 95 and 100% of APL cases have been reported to be associated with karyotypic abnormalities involving pathognomonic translocations at *t*(15;17)(q22--24;q11--21) that juxtapose the retinoic acid receptor α (RARα) gene with the promyelocytic leukemia (PML) gene ([@b6-ol-07-01-0177],[@b7-ol-07-01-0177]). This translocation has been implicated in the blockage of normal differentiation of immature myeloid cells into mature granulocytes ([@b8-ol-07-01-0177],[@b9-ol-07-01-0177]) and the inhibition of programmed cell death in myeloid cells ([@b7-ol-07-01-0177]). Furthermore, 10--50% of all patients with APL exhibit FLT3 mutations, either as internal tandem duplications or kinase domain mutations ([@b10-ol-07-01-0177]), and FLT3 mutations generally correlate with high white blood cell (WBC) counts (\>10×10^9^/l), which are indicative of higher patient risk of relapse ([@b6-ol-07-01-0177]).

ATRA treatments for APL are unique in that they act by dissociating the nuclear hormone receptor complex NCOR-HDAC from RARα. This then initiates the maturation of leukemic promyelocytes, rather than inducing cell death ([@b11-ol-07-01-0177]). While ATRA monotherapies have demonstrated relatively high relapse rates, combined therapies involving anthracyclines and other active agents are able to markedly reduce relapse rates ([@b12-ol-07-01-0177]). Arsenic compounds, such as arsenic trioxide (ATO) and arsenic tetrasulfide (ATS), are the most active single agents in refractory APL treatment due to their ability to induce partial myeloid differentiation and caspase-specific apoptosis ([@b13-ol-07-01-0177]), with a relapse rate of \<20% following monotherapy ([@b14-ol-07-01-0177]). Combined treatment regimens involving both ATRA and ATO have been reported to eradicate leukemic progenitor cells and reduce the relapse rate to \<10% in even high-risk patients with APL ([@b15-ol-07-01-0177]). Furthermore, combined ATRA- and arsenic compound-based (ATRA + arsenic compound) salvage therapies have been demonstrated to induce complete remission in 50--80% of refractory or relapsed patients with APL ([@b16-ol-07-01-0177]).

Though contemporary combined ATRA + arsenic compound therapies are effective in inducing complete remission (CR) in the majority of patients, a notable patient group still exhibits relapse, although the characteristics of this group are relatively undocumented. For these patients, the risks and benefits of ATRA + arsenic compound retreatment versus retreatment with other modalities remain controversial, as few evidence-based studies have specifically examined cohorts of relapsed patients with APL. The current study examines the characteristics and effectiveness of the treatment of first-time relapsed patients with APL that were originally treated with combined ATRA + arsenic compound therapies. The results provide a unique insight into the outcomes of these patients that is useful for the evaluation and selection of treatment strategies.

Materials and methods
=====================

Study design
------------

A total of 25 first-time relapse patients with APL, who were previously treated with first-line ATRA + arsenic compound therapy and were subsequently treated in the Hematological Unit of Peking University People's Hospital (Beijing, China) between January 1994 and December 2010, were included in this retrospective, observational analysis. The study protocol was approved by the Institutional Review Board at Peking University People's Hospital. All patients provided written informed consent, prior to their treatment, for the use of their data in the subsequent research.

Patients
--------

Patients were included that: i) were diagnosed with APL in accordance with the morphological criteria (M0--M7) of the French-American-British classification system for myelocytic leukemias ([@b17-ol-07-01-0177]); ii) exhibited APL confirmed by both cytogenetic assay for *t*(15;17)(q24;q21) and reverse transcription polymerase chain reaction (PCR) analysis for *PML-RARα*, as previously described by de Botton *et al*([@b18-ol-07-01-0177]); iii) underwent initial induction therapy with first-line ATRA (25 mg/m^2^/day) and low-dose cytotoxic agents, with or without adjuvant treatment with ATO (10 mg/kg/day) or up-titrated ATS (2250--60 mg/kg/day); iv) exhibited relapse, defined as any disease recurrence following CR, including morphological, molecular and extra-medullary relapses; and v) were treated with consolidation chemotherapy involving cytarabine (Ara-C)- or anthracycline-based therapies with alternating maintenance ATRA (25 mg/m^2^/day) for two weeks, once every three months, and ATO (10 mg/kg/day) or ATS (60 mg/kg/day) for two weeks, twice every three months. WBC and platelet counts were further used to classify patients as low risk (\<10×10^9^/l; \>40×10^9^/l), intermediate risk (\<10×10^9^/l; \<40×10^9^/l) or high risk (≥10×10^9^/l; \<40×10^9^/l), respectively, as previously described ([@b18-ol-07-01-0177]).

Relapse and re-induction therapy
--------------------------------

Following confirmation of APL relapse, appropriate re-induction regimens were immediately administered using one of six therapeutic regimens: i) ATRA + arsenic compound combination therapy (Ruijin Pharmaceuticals Co., Ltd., Shanghai, China); salvage chemotherapy with ii) mitoxantrone (Shenghe Pharmaceuticals Co., Ltd., Sichuan, China) + Ara-C (Pfizer, Inc., New York, NY, USA) (MA), iii) homoharringtonin (Minsheng Pharmaceutical Group Co., Ltd., Zhejiang, China) + Ara-C (HA), or iv) homoharringtonin + Ara-C + daunomycin (Pfizer, Inc.) (HAD); v) gemtuzumab ozogamicin treatment (Wyeth Pharmaceuticals, Philadelphia, PA, USA); or vi) intrathecal chemotherapy with cytarabine and dexamethasone (CSPC Zhongnuo Pharmaceutical Co., Ltd., Shijiazhuang, China). Relapse types were classified as morphological relapse (≥5% blasts per abnormal promyelocytes in the bone marrow or per leukemic cells in the peripheral blood), molecular relapse (*PML/RARα* gene conversion from PCR-negative to -positive in patients without morphological abnormalities in two successive four-week bone marrow samples) or extramedullary relapse (abnormal promyelocytes in the cerebrospinal fluid or extramedullary granulocytic sarcoma).

Laboratory monitoring and assessments
-------------------------------------

Follow-up bone marrow aspiration was repeated at three-month intervals during maintenance therapy (ATRA + arsenic compounds with alternating maintenance chemotherapy) administration. Patient tolerance, based on gastrointestinal reactions and hepatotoxicity (reduced drug dose when hepatotoxicity grade ≥3 and drug withdrawal when hepatotoxicity grade 4), and urine arsenic compounds were closely monitored, and the doses of arsenic compounds were adjusted in accordance with standards published by the National Cancer Institute ([@b19-ol-07-01-0177]).

Outcome assessments
-------------------

The patients were followed up for a minimum of six months after relapse treatment. The outcome of post-retreatment remission rates, duration of remission and toxic effects were recorded. CR was defined as \<5% blasts or abnormal promyelocytes in the bone marrow, coupled with peripheral blood absolute neutrophil count ≥1.5×10^9^/l, untransfused hemoglobin levels ≥100 g/l and platelet count ≥100×10^9^/l. Molecular remission was defined as a negative bone marrow PCR for the *PML*/*RARα* gene at a sensitivity of 10^−4^. Treatment with reconsolidation therapies and other therapies, such as allogeneic and autologous hematopoietic stem cell transplantation (allo-HSCT and auto-HSCT, respectively), were recorded.

Statistical analysis
--------------------

This was a retrospective, observational analysis and only descriptive statistics are provided. Data are presented as the mean ± standard deviation, the mean ± interquartile range or the percentile \[n (%)\], as appropriate.

Results
=======

Clinical characteristics of patients initially diagnosed with APL
-----------------------------------------------------------------

A total of 25 patients initially diagnosed with APL, 17 males and 8 females (mean age, 36.4±10.3 years; range, 19--64 years; [Table I](#tI-ol-07-01-0177){ref-type="table"}), were included in the study. Patients were followed up for a median of four years (range, 0.5--13 years) following their initial treatment (data not shown). According to the classification system by Sanz *et al*([@b4-ol-07-01-0177]), four patients (16.0%) were at low risk, 12 (48.0%) were at intermediate risk and nine (36.0%) were at high risk of ALP relapse ([Table I](#tI-ol-07-01-0177){ref-type="table"}). All patients were previously administered with ATRA and low-dose cytotoxic agents during initial induction therapy, and 16 patients (64.0%) received adjuvant treatment with ATO or up-titrated ATS. Thirteen patients (52.0%) received intrathecal chemotherapy for the treatment of central nervous system (CNS) involvement at the time of initial diagnosis, and all patients received prophylactic intrathecal chemotherapy following CR (data not shown).

Clinical characteristics of relapsed patients with APL
------------------------------------------------------

The first relapse occurred at a median of 17 months (range, 5--84 months) following initial treatment ([Table I](#tI-ol-07-01-0177){ref-type="table"}). Relapses involved bone marrow in 19 patients (76.0%), the CNS alone in one patient (4.0%), molecular relapse in one patient (4.0%) and bone marrow/CNS (complete relapse) in four patients (16.0%) ([Table II](#tII-ol-07-01-0177){ref-type="table"}). The relapsed patients with APL showed a median WBC count of 4.8×10^9^/l (range, 1.3--144.2×10^9^/l), a median hemoglobin level of 125.9±29.4 g/l (range, 63.9--182 g/l) and a median platelet count of 140.0×10^9^/l (range, 9.0--266.0×10^9^/l) ([Table I](#tI-ol-07-01-0177){ref-type="table"}). First relapse data is presented in comparison with initial clinical values in [Table I](#tI-ol-07-01-0177){ref-type="table"} and in full detail in [Table II](#tII-ol-07-01-0177){ref-type="table"}.

Re-induction therapy selection and efficacy
-------------------------------------------

Four relapsed patients with APL succumbed to the disease before re-induction therapy. For re-induction therapy, patients were treated with either ATRA + arsenic compound combination therapy (16/25, 64.0%), salvage chemotherapy with HA (2/25, 8.0%), salvage chemotherapy with HAD (1/25, 4.0%), gemtuzumab ozogamicin (for the single case of molecular relapse; 1/25, 4.0%) or intrathecal chemotherapy (for the single case of isolated CNS relapse; 1/25, 4.0%) ([Table II](#tII-ol-07-01-0177){ref-type="table"}). Two of those who did not survive (8.0%) were treated with ATRA + arsenic compound re-induction therapy. Only one (4.0%) patient recovered completely from isolated CNS relapse following intrathecal chemotherapy, remaining disease-free for 13 years. CR was also observed following ATRA + arsenic compound therapy (10/25, 40.0%), chemotherapy (3/25, 12.0%)and targeted therapy (1/25, 4.0%); and non-remission (NR) following ATRA + arsenic compounds (4/25, 16%) ([Table II](#tII-ol-07-01-0177){ref-type="table"}). [Fig. 1](#f1-ol-07-01-0177){ref-type="fig"} details the treatment and outcomes of the patients.

Reconsolidation therapy and survival
------------------------------------

Among the 19 surviving patients (76.0%), complete recovery from CNS relapse following intrathecal chemotherapy occurred in one patient (1/19, 5.3%); one patient (5.3%) treated with allo-HSCT following secondary CR remained disease-free at the end of the study period; two patients (10.5%) remained in CR following remission re-induction; secondary bone marrow and CNS relapse occurred in 14 patients (73.7%) and one patient (5.3%), respectively. The rate of secondary relapse was 78.9% (15/19) ([Table II](#tII-ol-07-01-0177){ref-type="table"}).

Among the 19 surviving patients (76.0%), complete recovery from CNS relapse following intrathecal chemotherapy occurred in one patient (1/25, 4.0%); one patient (4.0%) treated with allo-HSCT following secondary CR remained disease-free at the end of the study period; two patients (8.0%) remained in CR following remission re-induction; and secondary bone marrow and CNS relapse occurred in 14 patients (56.0%) and one patient (4.0%), respectively. The rate of secondary relapse was 78.9% (15/19) ([Table II](#tII-ol-07-01-0177){ref-type="table"}).

Toxic effects of ATRA + arsenic compound re-induction therapy
-------------------------------------------------------------

Adverse events were observed in all ATRA + arsenic compound re-induction therapy patients. Of the 16 surviving patients, six (6/16, 37.5%) exhibited no treatment-emergent toxicity, six (6/16, 37.5%) exhibited grade 1--2 hepatotoxicity, two (2/16, 12.5%) exhibited grade 3--4 bone marrow suppression and two (2/16, 12.5%) exhibited treatment-related mortality. Salvage chemotherapy was poorly tolerated in all three patients receiving chemotherapy for re-induction, with grades 3--4 bone marrow suppression. No toxicity was reported in the two patients that received isolated intrathecal chemotherapy or gemtuzumab ozogamicin ([Table II](#tII-ol-07-01-0177){ref-type="table"}).

Discussion
==========

The present study demonstrated that ATRA + arsenic compound-based combination therapy was effective in re-inducing morphological remission in relapsed patients with APL with previous exposure to ATRA + arsenic compounds; however, these patients remained subject to low molecular remission rates and at high risk of secondary relapse. Notably, allo-HSCT yielded good re-induction results, suggesting that early allo-HSCT should be more carefully explored as a therapeutic option for re-inducing morphological remission in relapsed patients with APL with previous exposure to ATRA + arsenic compounds.

Combinations of ATRA and chemotherapy have been widely accepted as front-line treatments for the majority of relapsed patients with APL ([@b12-ol-07-01-0177]). In the present study, the overall good results produced by ATRA + arsenic compounds, leading to remission in the majority of patients with APL, are consistent with a previous study that recommends this treatment for salvage patients with APL or those that have previously received ATRA-based combination therapies ([@b16-ol-07-01-0177]). Furthermore, arsenic compound monotherapy has been reported to effectively re-induce molecular remission in 80--90% of relapsed patients with APL, making it useful as both an initial induction and consolidation treatment in high-risk patients ([@b16-ol-07-01-0177]). Breccia *et al*([@b13-ol-07-01-0177]) reported that prolonged ATO-based salvage therapy achieved a high remission rate in relapsed ATO-naïve patients without requiring HSCT. Cumulatively, the results of the current study and the findings of these previous studies are in agreement and indicate that morphological remission in relapsed patients with APL with previous exposure to ATRA + arsenic compounds may be efficiently obtained using ATRA + arsenic compound-based combination therapy. Notably, these findings are generally consistent with the broader guidelines published by the National Comprehensive Cancer Network in 2011 ([@b20-ol-07-01-0177]).

In the patient cohort of the present study, APL relapse occurred at a median of 17 months after initial reports of CR, a relapse time significantly earlier than that reported by Thirugnanam *et al* (20.3 months) ([@b14-ol-07-01-0177]). A high remission re-induction rate was achieved in patients in the current study following ATRA + arsenic compound-based salvage treatment with or without chemotherapy, although these patients had previous exposure to ATRA + arsenic compounds. Furthermore, alternative chemotherapy was generally effective; however, these patients often experienced secondary relapse and the duration of remission was relatively short (median, 15 months). By contrast, Thirugnanam *et al*([@b14-ol-07-01-0177]) reported a CR rate of 93% in relapsed patients with APL with previous exposure to ATO monotherapy following ATRA + arsenic compound-based salvage treatment with or without anthracycline-based chemotherapy. Furthermore, these patients with APL only received ATRA as salvage treatment for relapse, rather than induction or maintenance therapy for initial treatment ([@b14-ol-07-01-0177]); whereas, the majority of patients in the current study received arsenic compounds induction and maintenance therapies as well. This may contribute to discrepancies between the findings of the current study and those of Thirugnanam *et al*([@b14-ol-07-01-0177]).

The current results indicated a high frequency of extra-medullary relapse, with the CNS involved in the relapse of approximately one fifth of current patients, and this was inconsistent with a previous study in which only 8% of patients exhibited relapse in the CNS ([@b14-ol-07-01-0177]). Furthermore, the majority of patients in the present study with CNS relapse also exhibited relapse in the bone marrow. As ATRA upregulates the expression of adhesion molecules, such as CD11b, CD13 and CD56, on ALP cell surfaces ([@b21-ol-07-01-0177]), and concomitantly stimulates the secretion of interleukin-1 ([@b22-ol-07-01-0177]), ATRA promotes endothelial expression of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 ([@b23-ol-07-01-0177]). As a result, patients with APL exposed to ATRA are more likely to exhibit relapse involving the CNS or even the pseudotumor cerebri ([@b4-ol-07-01-0177]), which may explain the occurrence of relapse in the CNS in the patients of the present study. Additionally, granulocytosis may independently contribute to CNS involvement during ALP relapse ([@b24-ol-07-01-0177]), further raising the risk of relapse involving the CNS.

Only a small percentage of the patients in the current study achieved molecular remission, suggesting that relapsed patients with APL previously exposed to ATRA + arsenic compound-based combination treatments were at very high risk of secondary relapse. Notably, all the patients previously treated with ATRA + arsenic compounds combined with chemotherapy exhibited relapse following auto-HSCT. Therefore, auto-HSCT may not be suitable for these patients, despite general recommendations that auto-HSCT rather than allo-HSCT is optimal for use in patients with APL who initially achieve CR following primary relapse ([@b25-ol-07-01-0177]). By contrast, allo-HSCT should be considered in relapsed patients that exhibit a relatively short duration of remission or do not achieve molecular remission, preferably following the secondary rather than tertiary morphological CR episode ([@b26-ol-07-01-0177]).

As all the patients included in the current study were exposed to ATRA, further comparative studies are required to identify whether ATRA is involved in the development of CNS relapse and by which mechanisms this action may occur. Additionally, variations in dosage and treatment duration must be considered, which may contribute to relapse occurrence based on yet undetermined risk factors. Furthermore, the sample size of the present study is relatively small and, thus, may not be fully representative of broader APL patient populations.

ATRA + arsenic compound-based salvage treatments with or without chemotherapy are effective agents for re-inducing complete remission in relapsed patients with APL previously exposed to combined ATRA + arsenic compound therapies. Molecular remission, however, is relatively rare following such salvage treatment in relapsed patients with APL, and the vast majority of these patients will exhibit secondary relapse. Furthermore, the findings of the present study suggest that auto-HSCT may be unsuitable for use in relapsed patients with APL who are at high risk of secondary relapse, with early allo-HSCT yielding a more notable beneficial survival benefit. Large-scale comparative studies, however, will be required to fully elucidate this correlation.

![Flowchart of patient treatment and outcome data. APL, acute promyelocytic leukemia; CNS, central nervous system; allo-HSCT, allogeneic hematopoietic stem cell transplantation.](OL-07-01-0177-g00){#f1-ol-07-01-0177}

###### 

Demographic and clinical characteristics of patients with acute promyelocytic leukemia at the time of initial diagnosis and first relapse.

                                                                             Value       
  -------------------------------------------------------------------------- ----------- -------------
  Gender, n (%)                                                                          
   Male                                                                      17 (68.0)   
   Female                                                                    8 (32.0)    
  Age, years                                                                 36.4±10.3   
  WBC count, 10^9^/l[a](#tfn2-ol-07-01-0177){ref-type="table-fn"}            7.8±16.6    4.8±2.7
  Hemoglobin, g/dl[a](#tfn2-ol-07-01-0177){ref-type="table-fn"}              99.0±52.0   125.9±29.4
  DIC, n (%)                                                                 12 (48.0)   9 (36.0)
  CNS leukemia, n (%)                                                        13 (52.0)   11 (44.0)
  Sanz risk category[b](#tfn3-ol-07-01-0177){ref-type="table-fn"}, n (%)                 
   Low risk                                                                  4 (16.0)    
   Intermediate risk                                                         12 (48.0)   
   High risk                                                                 9 (36.0)    
  Platelet count, 10^9^/l[a](#tfn2-ol-07-01-0177){ref-type="table-fn"}       28.2±33.0   140.0±139.0
  Chromosome aberration, n (%)                                               7 (28.0)    
   Equiarm 17q                                                               1 (4.0)     
   +2p−, −4, inv(14), 22p+, +mar                                             1 (4.0)     
   +8                                                                        1 (4.0)     
   1p+, 16q+                                                                 1 (4.0)     
   7q−                                                                       1 (4.0)     
   16p+, 14q−                                                                1 (4.0)     
   11p+, 17p−, −14, −20, ace[a](#tfn2-ol-07-01-0177){ref-type="table-fn"}2   1 (4.0)     
  CD56 expression, n (%)                                                                 
   Negative                                                                  6 (24.0)    
   Positive                                                                  3 (12.0)    
   Unknown                                                                   16 (64.0)   
  CD117 expression, n (%)                                                                
   Negative                                                                  1 (4.0)     
   Positive                                                                  11 (44.0)   
   Unknown                                                                   13 (52.0)   
  Time to relapse, months[a](#tfn2-ol-07-01-0177){ref-type="table-fn"}       17.0±17.0   15.0±17.0

Patients were initially treated with all-*trans* retinoic acid and arsenic compound-based combined therapies. Data are presented as the mean ± SD unless otherwise specified.

The median ± interquartile range.

Category taken from ([@b4-ol-07-01-0177]).

WBC, white blood cell; DIC, disseminated intravascular coagulation; CNS, central nervous system.

###### 

Clinical characteristics of patients with acute promyelocytic leukemia at the time of first relapse.

  Characteristics                    n (%)
  ---------------------------------- -----------
  Relapse type                       
   Bone marrow                       19 (76.0)
   CNS alone                         1 (4.0)
   Molecular                         1 (4.0)
   Bone marrow/CNS                   4 (16.0)
  First relapse induced              
   ATRA + arsenic compounds          16 (64.0)
   ED                                4 (16.0)
   GO                                1 (4.0)
   Salvage chemotherapy              3 (12.0)
   Intrathecal chemotherapy          1 (4.0)
  Induced side effects               
   ED                                6 (24.0)
   Grade 1 hepatotoxicity            2 (8.0)
   Grade 2 hepatotoxicity            4 (16.0)
   Grade 3 bone marrow suppression   4 (16.0)
   Grade 4 bone marrow suppression   1 (4.0)
   None                              8 (32.0)
  First recurrence consolidate       
   ATRA + arsenic compounds          
   with alternating chemotherapy     9 (36.0)
   ED                                6 (24.0)
   GO                                1 (4.0)
   Chemotherapy alone                4 (16.0)
   Arsenic compounds                 2 (8.0)
   None                              3 (12.0)
  First relapse treatment efficacy   
   CR                                15 (60.0)
   ED                                6 (24.0)
   NR                                4 (16.0)
  Second relapse                     
   ED                                6 (24.0)
   Non-relapse                       4 (16.0)
   Relapse                           15 (60.0)
  Third relapse                      
   ED                                11 (44.0)
   Non-relapse                       6 (24.0)
   Died of allo-HSCT                 2 (8.0)
   Relapse                           6 (24.0)
  Current Status                     
   CR                                8 (32.0)
   Death                             17 (68.0)

Patients were initially treated with all-*trans* retinoic acid and arsenic compound-based combined therapies. CNS, central nervous system; ATRA, all-*trans* retinoic acid; ED, early death; GO, gemtuzumab ozogamicin; CR, complete remission; NR, non-remission; allo-HSCT: allogeneic hematopoietic stem cell transplantation.
